Pfizer Receives All Required Regulatory Approvals To Complete Seagen Acquisition
(RTTNews) - Pfizer Inc. (PFE) announced Tuesday that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired December 11, 2023, with respect to Pfizer's pending acquisition of Seagen Inc. (SGEN).
Pfizer and Seagen have now received all required regulatory approvals to complete the acquisition. Pfizer expects to close the acquisition of Seagen on December 14, 2023, subject to the satisfaction of other customary closing conditions.
Pfizer also announces changes in its commercial organization to incorporate Seagen and improve focus, speed and quality of execution. The new organization structure will go into effect January 1, 2024.
read more
Pfizer Launches Digital Platform PfizerForAll
Drug giant Pfizer Inc. (PFE) announced Tuesday the introduction of PfizerForAll, a user-friendly digital platform designed to make access to healthcare and managing health and wellness more seamless for people across the U.S.
RTTNews
|
vor 121 Tagen
FDA Approves Updated Pfizer, Moderna Covid Vaccines Against Current Variants
The U.S. Food and Drug Administration approved and granted emergency use authorization or EUA for updated Covid vaccines from Pfizer Inc. and ModernaTX Inc. for use against currently circulating variants. The approval for the updated mRNA COVID-19 vaccines (2024-2025 formula) comes as the Covid cases are surging in the United States.
RTTNews
|
vor 125 Tagen
Pfizer, BioNTech Announce Top-line Results In Phase 3 Trial Of MRNA-based Combination Vaccine
Drug giant Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced Friday top-line results from their Phase 3 clinical trial to evaluate the companies' combined mRNA vaccine candidate against influenza and COVID-19 in healthy individuals 18-64 years of age.
RTTNews
|
vor 132 Tagen
Pfizer Boost FY24 Outlook - Update
While reporting financial results for the second quarter, drug major Pfizer Inc. (PFE) raised its adjusted earnings and revenue guidance for the full-year 2024.
RTTNews
|
vor 149 Tagen
Pfizer Advances Once-Daily Formulation Of Oral GLP-1 Receptor Agonist Danuglipron
Drug major Pfizer, Inc. (PFE) announced Thursday that the company has selected its preferred once-daily modified release formulation for danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist, based on results from the ongoing pharmacokinetic study (NCT06153758).
RTTNews
|
vor 168 Tagen
Pfizer's Hospira Recalls Select Hydrochloride Injection Carpuject Units
Hospira, Inc., affiliated to dug major Pfizer Inc., is recalling select lots of Buprenorphine Hydrochloride Injection Carpuject Units and Labetalol Hydrochloride Injection Carpuject Units, according to the U.S. Food and Drug Administration. The recall was initiated due to the potential for incomplete crimp seals. The company has received one customer complaint for one leaking unit.
RTTNews
|
vor 217 Tagen
Amazon, Microsoft, Pfizer To Invest Billions In French Projects
Major companies, including Amazon.com Inc., Microsoft Corp., Morgan Stanley, Pfizer and others, have announced around 15 billion euros or $16.2 billion worth foreign investments in France as part of the country's annual 'Choose France' business summit, reports said. French President Emmanuel Macron kicks off the summit of 180 CEOs and executives on Monday, aiming to showcase foreign investment.
RTTNews
|
vor 227 Tagen
Pfizer Boost FY24 Adj. EPS Outlook - Update
While reporting financial results for the first quarter, drug major Pfizer Inc. (PFE) raised its adjusted earnings guidance for the full-year 2024, while maintaining annual revenue outlook.
RTTNews
|
vor 239 Tagen
